Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer

Malolan S. Rajagopalan, Dwight E. Heron, Rodney E. Wegner, Herbert J. Zeh, Nathan Bahary, Alyssa M. Krasinskas, Barry Lembersky, Randall Brand, A. J. Moser, Annette E. Quinn, Steven A. Burton

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Background: Neoadjuvant stereotactic body radiotherapy (SBRT) has potential applicability in the management of borderline resectable and locally-advanced pancreatic adenocarcinoma. In this series, we report the pathologic outcomes in the subset of patients who underwent surgery after neoadjuvant SBRT. Methods: Patients with borderline resectable or locally-advanced pancreatic adenocarcinoma who were treated with SBRT followed by resection were included. Chemotherapy was to the discretion of the medical oncologist and preceded SBRT for most patients. Results: Twelve patients met inclusion criteria. Most (92%) received neoadjuvant chemotherapy, and gemcitabine/capecitabine was most frequently utilized (n = 7). Most were treated with fractionated SBRT to 36 Gy/3 fractions (n = 7) and the remainder with single fraction to 24 Gy (n = 5). No grade 3+ acute toxicities attributable to SBRT were found. Two patients developed post-surgical vascular complications and one died secondary to this. The mean time to surgery after SBRT was 3.3 months. An R0 resection was performed in 92% of patients (n = 11/12). In 25% (n = 3/12) of patients, a complete pathologic response was achieved, and an additional 16.7% (n = 2/12) demonstrated <10% viable tumor cells. Kaplan-Meier estimated median progression free survival is 27.4 months. Overall survival is 92%, 64% and 51% at 1-, 2-, and 3-years. Conclusions: This study reports the pathologic response in patients treated with neoadjuvant chemotherapy and SBRT for borderline resectable and locally-advanced pancreatic cancer. In our experience, 92% achieved an R0 resection and 41.7% of patients demonstrated either complete or extensive pathologic response to treatment. The results of a phase II study of this novel approach will be forthcoming.

Original languageEnglish (US)
Article number254
JournalRadiation Oncology
Volume8
Issue number1
DOIs
StatePublished - Oct 31 2013
Externally publishedYes

Keywords

  • Neoadjuvant
  • Pancreatic cancer
  • Pathologic response
  • SBRT
  • Stereotactic body radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    Rajagopalan, M. S., Heron, D. E., Wegner, R. E., Zeh, H. J., Bahary, N., Krasinskas, A. M., Lembersky, B., Brand, R., Moser, A. J., Quinn, A. E., & Burton, S. A. (2013). Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiation Oncology, 8(1), [254]. https://doi.org/10.1186/1748-717X-8-254